The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA)
Gout, Urate, and Crystal Deposition Disease · 2023
DOI: 10.3390/gucdd1020009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, 2023. Verfasst von Surbhi Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, Claude D. Pepper Older American Independence Centers.
Abstract (Originalsprache)
(1) The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-center longitudinal cohort study designed to investigate the risk factors associated with the incidence of CVD. The purpose of this study is to examine the impact of gout on incident CVD. (2) Participants reporting the use of gout-specific medications (urate lowering drugs or colchicine) were compared with non-users. Kaplan–Meier survival curves and multivariable models to control for known CV risk factors evaluated hazard ratios (HR) between participants taking gout medications versus those not taking gout medications. (3) For the 6734 participants, analyses were stratified by gender owing to a gout-gender interaction. For the 164 male and 59 female participants taking gout medications, Kaplan–Meier (unadjusted) survival curves demonstrate that participants taking gout medications have higher rates of CVD than participants not taking gout medications, particularly for women. After controlling for known CV risk factors, the adjusted HR for female participants taking gout medications was 1.79 (0.99, 3.23), p = 0.05; the adjusted HR for male participants on gout medications was 1.20 (0.81, 1.77), p = 0.36; (4) Participants treated for gout in this study have many comorbid conditions with known CVD risk factors, making it difficult to confirm the independent effect of gout on CVD. There are a paucity of data on women with gout. These findings suggest that there is a clinically meaningful and potentially greater risk of CVD among women with gout as compared to men.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
ORCID-Profile: John D FitzGerald
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- Claude D. Pepper Older American Independence Centers
- NCATS
- MESA study
Zitieren
APA
Gupta, S., Miller, E., Merkin, S. S., McMahon, M., Karol E, W., & FitzGerald, J. D. (2023). The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA). Gout, Urate, and Crystal Deposition Disease. https://doi.org/10.3390/gucdd1020009
Vancouver
Gupta S, Miller E, Merkin SS, McMahon M, Karol E W, FitzGerald JD. The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA). Gout, Urate, and Crystal Deposition Disease. 2023. doi:10.3390/gucdd1020009
BibTeX
@article{Gupta2023,
author = {Gupta, Surbhi and Miller, Elizabeth and Merkin, Sharon Stein and McMahon, Maureen and Karol E, Watson and FitzGerald, John D},
title = {The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA)},
journal = {Gout, Urate, and Crystal Deposition Disease},
year = {2023},
doi = {10.3390/gucdd1020009}
}
EUVIMED